SCHEMBL2487359

SCHEMBL2487359

Cc1cc(-c2ccc(C)nc2C(=O)O)on1.[LiH]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
USP2 O75604 1/20 0.56
TSHR P16473 1/20 0.56
HCAR2 Q8TDS4 1/20 0.45
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPK1 P28482 1/20 0.43
HCRTR2 O43614 3/20 0.42
HCRTR1 O43613 2/20 0.42
POLB P06746 1/20 0.39
BRD4 O60885 1/20 0.39
LMNA P02545 2/20 0.37
RECQL P46063 1/20 0.36
HTT P42858 1/20 0.35
RARA P10276 1/20 0.35
RXRA P19793 1/20 0.35
RXRG P48443 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9955618 0.98 ALDH1A1 (0.57) ALDH1A1KDM4EUSP2TSHRHCAR2
Lithium Ion SCHEMBL2487357 0.84 KDM4E (0.48) ALDH1A1KDM4EUSP2TSHRHCAR2
SCHEMBL2473885 0.82 KDM4E (0.47) ALDH1A1KDM4EUSP2TSHRKMT2A
SCHEMBL609369 0.77 KMT2A (0.47) ALDH1A1KDM4EUSP2TSHRHCAR2
SCHEMBL10262356 0.75 KDM4E (0.46) ALDH1A1KDM4EUSP2TSHRKMT2A
SCHEMBL31123937 0.74 ALDH1A1 (0.50) ALDH1A1KDM4EUSP2TSHRHCAR2
SCHEMBL2476367 0.72 HCRTR2 (0.42) ALDH1A1KDM4EUSP2KMT2AMAPK1
SCHEMBL9955877 0.72 KDM4E (0.44) ALDH1A1KDM4EUSP2TSHRKMT2A
SCHEMBL16042101 0.72 HCRTR2 (0.41) ALDH1A1KDM4EUSP2TSHRHCAR2
SCHEMBL609807 0.72 GAA (0.40) ALDH1A1TSHRLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379550-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS Glaxo Group Limited (GB) 2011-10-26 EP disclosed
US-20110257198-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2011-10-20 US disclosed
WO-2010072722-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-07-01 WO disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257198-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, VIPR2 ALDH1A1 1507/4885KDM4E 1459/4885USP2 3775/4885
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B ALDH1A1 882/4885KDM4E 1224/4885USP2 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.